Journal of Clinical Oncology, Vol 18, Issue 13
(July), 2000: 2603-2606
© 2000 American Society for Clinical Oncology
Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients
By Pier Luigi Zinzani,
Gianandrea Baliva,
Massimo Magagnoli,
Maurizio Bendandi,
Gino Modugno,
Filippo Gherlinzoni,
Giulio Fraternali Orcioni,
Stefano Ascani,
Romeo Simoni,
Stefano A. Pileri,
Sante Tura
From the Institute of Hematology and Medical Oncology "Seràgnoli," University of Bologna, and Institute of Dermatology "Immacolata," Rome, Italy.
Address reprint requests to Pier Luigi Zinzani, MD, Istituto di Ematologia ed Oncologia Medica "L. e A. Seràgnoli," Policlinico S. Orsola, Via Massarenti 9, 40138 Bologna, Italy; email plzinzo{at}med.unibo.it
PURPOSE: To evaluate the efficacy and toxicity of gemcitabine, a novel pyrimidine antimetabolite with a low-toxicity profile and activity in several solid tumors, in patients with relapsed or refractory cutaneous T-cell lymphomas.
PATIENTS AND METHODS: Between May 1997 and February 1999, 44 previously treated patients with mycosis fungoides (MF; n = 30) and peripheral T-cell lymphoma unspecified (PTCLU) with exclusive skin involvement (n = 14) were enrolled onto a two-institution, phase II trial and treated with gemcitabine. This drug was given on days 1, 8, and 15 of a 28-day schedule at a dose of 1,200 mg/m2 intravenously over 30 minutes for a total of three courses.
RESULTS: Of the 44 patients, five (11.5%) achieved complete responses (CRs), 26 (59%) partial responses (PRs), and the remaining 13 showed no benefit from the treatment. Two of the CRs were histologically confirmed. The CR and PR rates were the same for patients with MF and those with PTCLU, respectively. No difference in terms of overall response rate was observed between relapsed and refractory patients. The median durations of CR and PR were 15 months (range, 6 to 22 months) and 10 months (range, 2 to 15 months), respectively. Treatment was well tolerated; hematologic toxicity was mild, and no nausea/vomiting or organ toxicity was recorded.
CONCLUSION: The results of the present phase II study show activity of gemcitabine as a single agent in patients with pretreated cutaneous T-cell lymphoma. Further studies that use gemcitabine alone or in combination with other drugs in earlier stages of the disease are needed.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Quereux, S. Marques, J.-M. Nguyen, C. Bedane, M. D'incan, O. Dereure, E. Puzenat, A. Claudy, L. Martin, P. Joly, et al.
Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sezary Syndrome
Arch Dermatol,
June 1, 2008;
144(6):
727 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Le Gouill, N. Milpied, A. Buzyn, R. Peffault De Latour, J.-P. Vernant, M. Mohty, M.-P. Moles, K. Bouabdallah, C.-E. Bulabois, J. Dupuis, et al.
Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
J. Clin. Oncol.,
May 10, 2008;
26(14):
2264 - 2271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Horwitz
Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas
Hematology,
January 1, 2008;
2008(1):
289 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, G. Musuraca, M. Tani, V. Stefoni, E. Marchi, M. Fina, C. Pellegrini, L. Alinari, E. Derenzini, A. de Vivo, et al.
Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
J. Clin. Oncol.,
September 20, 2007;
25(27):
4293 - 4297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-T. Arkenau, G. Chong, D. Cunningham, D. Watkins, B. Sirohi, I. Chau, A. Wotherspoon, A. Norman, A. Horwich, and E. Matutes
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience
Haematologica,
February 1, 2007;
92(2):
271 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Weidmann, M. Gramatzki, M. Wilhelm, and P. S. Mitrou
Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting
Ann. Onc.,
March 1, 2004;
15(3):
369 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Baetz, A. Belch, S. Couban, K. Imrie, J. Yau, R. Myers, K. Ding, N. Paul, L. Shepherd, J. Iglesias, et al.
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group
Ann. Onc.,
December 1, 2003;
14(12):
1762 - 1767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Nabhan, D. Gajria, N. L. Krett, V. Gandhi, K. Ghias, and S. T. Rosen
Caspase Activation Is Required for Gemcitabine Activity in Multiple Myeloma Cell Lines
Mol. Cancer Ther.,
November 1, 2002;
1(13):
1221 - 1227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey
Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia
J. Clin. Oncol.,
February 1, 2002;
20(3):
665 - 673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors, E. D. Hsi, and F. M. Foss
Lymphoma of the Skin
Hematology,
January 1, 2002;
2002(1):
263 - 282.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. L. Piekarz, R. Robey, V. Sandor, S. Bakke, W. H. Wilson, L. Dahmoush, D. M. Kingma, M. L. Turner, R. Altemus, and S. E. Bates
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
Blood,
November 1, 2001;
98(9):
2865 - 2868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology,
January 1, 2001;
2001(1):
259 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
